- Home
- IPSC vs ICCM Comparison
IPSC vs ICCM Comparison
Compare IPSC & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- ICCM
- Stock Information
- Founded
- IPSC 2019
- ICCM 2006
- Country
- IPSC United States
- ICCM Israel
- Employees
- IPSC N/A
- ICCM N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- ICCM
- Sector
- IPSC Health Care
- ICCM
- Exchange
- IPSC Nasdaq
- ICCM Nasdaq
- Market Cap
- IPSC 45.4M
- ICCM 45.5M
- IPO Year
- IPSC 2021
- ICCM N/A
- Fundamental
- Price
- IPSC $0.55
- ICCM $0.72
- Analyst Decision
- IPSC Strong Buy
- ICCM Strong Buy
- Analyst Count
- IPSC 6
- ICCM 1
- Target Price
- IPSC $3.00
- ICCM $2.50
- AVG Volume (30 Days)
- IPSC 1.5M
- ICCM 441.9K
- Earning Date
- IPSC 11-13-2025
- ICCM 11-19-2025
- Dividend Yield
- IPSC N/A
- ICCM N/A
- EPS Growth
- IPSC N/A
- ICCM N/A
- EPS
- IPSC N/A
- ICCM N/A
- Revenue
- IPSC $113,337,000.00
- ICCM $2,975,000.00
- Revenue This Year
- IPSC $1,589.94
- ICCM $2.92
- Revenue Next Year
- IPSC N/A
- ICCM $57.81
- P/E Ratio
- IPSC N/A
- ICCM N/A
- Revenue Growth
- IPSC 4122.69
- ICCM N/A
- 52 Week Low
- IPSC $0.34
- ICCM $0.59
- 52 Week High
- IPSC $1.83
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- IPSC 52.98
- ICCM 46.69
- Support Level
- IPSC $0.46
- ICCM $0.68
- Resistance Level
- IPSC $0.56
- ICCM $0.75
- Average True Range (ATR)
- IPSC 0.04
- ICCM 0.05
- MACD
- IPSC 0.00
- ICCM 0.01
- Stochastic Oscillator
- IPSC 76.21
- ICCM 82.25
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.